KDMN Stock Performance, Insider Transaction and News

KDMN - Kadmon Holdings, Inc.

Market Cap	1.70B	P/E	-	EPS this Y	-10.40%	Ern Qtrly Grth	-
Income	-122.41M	Forward P/E	-14.18	EPS next Y	9.50%	50D Avg Chg	10.00%
Sales	19.67M	PEG	-	EPS past 5Y	-	200D Avg Chg	78.00%
Dividend	N/A	Price/Book	N/A	EPS next 5Y	-	52W High Chg	-
Recommedations	2.70	Quick Ratio	6.26	Shares Outstanding	178.52M	52W Low Chg	175.00%
Insider Own	0.16%	ROA	-29.66%	Shares Float	132.31M	Beta	1.12
Inst Own	103.71%	ROE	-153.99%	Shares Shorted/Prior	28.53M/24.02M	Price	9.50
Gross Margin	94.95%	Profit Margin	-	Avg. Volume	10,033,074	Target Price	12.10
Oper. Margin	-595.00%	Earnings Date	Nov 4	Volume	10,424,582	Change	0.00%

Healthcare | Biotechnology | United States

About Kadmon Holdings, Inc.

Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include Belumosudil (KD025), an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2 (ROCK2), which is in Phase II clinical trial for the treatment of chronic graft-versus-host, as well as systemic sclerosis, an autoimmune disease characterized by chronic inflammation, fibrosis, and vascular damage; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. Kadmon Holdings, Inc., was incorporated in 2010 and is headquartered in New York, New York. As of November 9, 2021, Kadmon Holdings, Inc. operates as a subsidiary of Sanofi.

KDMN Chatroom

Stocktoberfest Posted - 10 months ago

@StockmoverTr Ja bei $KDMN. Die haben mit Ablauf des PDUFA die Zulassung für ihr Medikament rezurok bekommen, was bei Blut und Knochenkrebs hilft. Zwei Monate später hat Sanofi knapp 2 Milliarden geboten. Woher ich komme, da kommst selber drauf. 😉

Stocktoberfest Posted - 11 months ago

@M1chaelJ0seph yes same as $KDMN years ago. The CEO was in jail and wasn't allowed to run the company anymore. Then his brother did. What happened is history.

Stocktoberfest Posted - 1 year ago

@Ajmh that reminds me of old $KDMN days. Especially pomerantz was quite active. Never heard anything after bo.

Stocktoberfest Posted - 10/31/23

@We_Like_daStooooock I think the question is, how high is a possible monetarization of the upcoming product. A positive example was $KDMN with the third line drug rezurok. Negative in my eyes would be $VBIV. They had a successful pdufa for some vaccine and no one seemed to care. What is your opinion about $CKPT and cosi?

zedma Posted - 1 year ago

$MCRB if you think goldman has any clue, look at the history. I did research about some acquired biotech companies, share price at acquisition and price target by goldman, a vast majority didn't make any sense. Here are a few notable ones $KDMN goldman pt right before acquisition $4 acquired at $9.5, $ARCT price target by goldman right before acquisition $62 but was acquired at $130, $DTIL PT by goldman was $18 but acquired at $37, $THOR pt by goldman $28 but acquired at $68

Quantisnow Posted - 1 year ago

$MGTX $OVID $KDMN 📰 Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors https://quantisnow.com/i/4414149?utm_source=stocktwits 45 seconds delayed.

risenhoover Posted - 03/26/23

$KDMN KDMN / Kadmon Holdings Inc Price Target Updated https://fintel.io/sfo/us/kdmn?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

risenhoover Posted - 03/25/23

$KDMN KDMN / Kadmon Holdings Inc Price Target Updated https://fintel.io/sfo/us/kdmn?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

risenhoover Posted - 03/23/23

$KDMN KDMN / Kadmon Holdings Inc Price Target Updated https://fintel.io/sfo/us/kdmn?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

risenhoover Posted - 03/22/23

$KDMN KDMN / Kadmon Holdings Inc Price Target Updated https://fintel.io/sfo/us/kdmn?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget